BioMarin Pharmaceutical (BMRN) drew fresh attention after presenting new VOXZOGO and BMN 333 data at ENDO 2026, reinforcing its focus on rare bone growth disorders and raising new questions for investors.

Against this backdrop, BioMarin Pharmaceutical’s 1 month share price return of 7.41% stands in contrast to a year to date share price decline of 6.39%. Over 3 years, the total shareholder return is down 42.21%, suggesting momentum has been uneven as investors reassess growth potential and risk around its rare disease portfolio.

If VOXZOGO and BMN 333 have caught your attention, it could be worth widening the lens and checking out other companies in the sector using our 39 healthcare AI stocks

With BioMarin Pharmaceutical’s shares down over multi year periods but trading at a steep discount to some analyst and intrinsic value estimates, you have to ask: is this a genuine mispricing, or is the market already baking in future growth?

Most Popular Narrative: 36.7% Undervalued

BioMarin Pharmaceutical’s most followed valuation narrative points to a fair value of $87.85 against a last close of $55.65, putting a spotlight on how much earnings power VOXZOGO and the broader rare disease portfolio might contribute over time.

Strong year over year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top line revenue growth.

Curious what kind of revenue path and margin profile sit behind that fair value estimate? The narrative leans heavily on compounding earnings and a future profit multiple that is closer to established biotech leaders than to early stage developers, built around assumptions that may look bold once you see them in black and white.

The fair value in this narrative is built using a 7.32% discount rate and a view that BioMarin Pharmaceutical can compound both revenue and earnings meaningfully from today’s base. Analysts contributing to this narrative also frame expectations for profitability several years out, which helps explain why the $87.85 fair value comes in well above the current $55.65 share price, even as there is wide dispersion between the most optimistic and most cautious forecasts.

Result: Fair Value of $87.85 (UNDERVALUED)

However, BioMarin Pharmaceutical’s story could change quickly if competition in rare disease growth disorders intensifies, or if higher R&D and SG&A spending pressures future earnings.

Another View: What Multiples Say About BioMarin Pharmaceutical Stock

While the fair value narrative points to BioMarin Pharmaceutical looking undervalued at $55.65 versus $87.85, the current P/E of 40x paints a different picture. That multiple sits well above the US Biotechs industry at 16.5x, the peer average at 28.2x, and the fair ratio of 26.2x. This raises the question of whether the share price already reflects a lot of optimism.

Next Steps

If the mix of optimism and concern around BioMarin Pharmaceutical leaves you undecided, move quickly from headline impressions to your own judgment using our 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond BioMarin Pharmaceutical?

If BioMarin Pharmaceutical has sharpened your focus, do not stop here. Broadening your watchlist now can help you spot opportunities before sentiment shifts.

• Spot potential high growth stories early by reviewing the 23 elite penny stocks with strong financials that already screen well on financial quality.
• Target value oriented opportunities by scanning the 47 high quality undervalued stocks that combine attractive pricing with solid fundamentals.
• Prioritize resilience and capital strength by using the solid balance sheet and fundamentals stocks screener (48 results) to highlight companies with sturdier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.